Exciting breakthroughs in the management of diabetes mellitus

[en] Remarkable advances were observed in recent years in the management of patients with type 2 (T2DM) or type 1 (T1DM) diabetes mellitus. Regarding T2DM, changes in treatment paradigms were observed, moving from a glucocentric approach to a multi-risk strategy and, finally, in people at high risk, to a specific cardiorenal protection using new antidiabetic agents. Regarding T1DM, progresses combined new insulin analogues with better pharmacokinetics, continuous and flash glucose monitoring and improved insulin delivery systems with smart insulin pens and insulin pumps connected to glucose monitoring device, allowing better glucose control with less hypoglycaemia. Because of an increasing variety of therapeutic approaches, an individualized patient-centred strategy is recommended, ideally with the collaboration of a multidisciplinary team. Shared care, connected care and tele-medicine will play an increasing role in the management of T1DM, and most probably also T2DM, in a near future.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

English

Title :

Exciting breakthroughs in the management of diabetes mellitus

Publication date :

2021

Journal title :

Diabetes Epidemiology and Management

eISSN :

2666-9706

Volume :

Pages :

100005

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.sciencedirect.com/science/article/pii/S2666970621000056

Available on ORBi :

since 01 February 2024

Statistics

Number of views

10 (1 by ULiège)

Number of downloads

15 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Polonsky, K.S, The past 200 years in diabetes. N Engl J Med 367 (2012), 1332–1340.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care, 44, 2021 S111-S24.
American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes-2021. Diabetes Care 44 (2021), S85–S99.
Tahrani, A.A., Barnett, A.H., Bailey, C.J, Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12 (2016), 566–592.
Defronzo, R.A, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
Drucker, D.J., Nauck, M.A, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
Scheen, A.J, Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Warmbrunn, M.V., Herrema, H., Aron-Wisnewsky, J., Soeters, M.R., Van Raalte, D.H., Nieuwdorp, M, Gut microbiota: a promising target against cardiometabolic diseases. Expert Rev Endocrinol Metab 15 (2020), 13–27.
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41 (2020), 255–323.
American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care, 44, 2021 S125-S50.
Gaede, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.H., et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59 (2016), 2298–2307.
Rawshani, A., Rawshani, A., Franzen, S., Eliasson, B., Svensson, A.M., Miftaraj, M., et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376 (2017), 1407–1418.
Kristensen, S.L., Rorth, R., Jhund, P.S., Docherty, K.F., Sattar, N., Preiss, D., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabet Endocrinol 7 (2019), 776–785.
Palmer, S.C., Tendal, B., Mustafa, R.A., Vandvik, P.O., Li, S., Hao, Q., et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, 372, 2021, m4573.
Scheen, A.J, Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes Metab 46 (2020), 181–185.
Marx, N., Davies, M.J., Grant, P.J., Mathieu, C., Petrie, J.R., Cosentino, F., et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol 9 (2021), 46–52.
Sattar, N, Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future. BMC Med, 17, 2019, 46.
Van Gaal, L., Scheen, A, Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38 (2015), 1161–1172.
Rubino, F., Nathan, D.M., Eckel, R.H., Schauer, P.R., Alberti, K.G., Zimmet, P.Z., et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a Joint statement by international diabetes organizations. Diabetes Care 39 (2016), 861–877.
Scheen, A.J, Precision medicine: the future in diabetes care?. Diabetes Res Clin Pract 117 (2016), 12–21.
Marshall, S.M, Celebrating 100 years of insulin. Diabetologia 64 (2021), 944–946.
Misra, S., Mathieu, C, Are newer insulin analogues better for people with Type 1 diabetes?. Diabet Med 37 (2020), 522–531.
Jarosinski, M.A., Dhayalan, B., Rege, N., Chatterjee, D., Weiss, M.A, Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues. Diabetologia 64 (2021), 1016–1029.
Beck, R.W., Bergenstal, R.M., Laffel, L.M., Pickup, J.C, Advances in technology for management of type 1 diabetes. Lancet 394 (2019), 1265–1273.
Danne, T., Nimri, R., Battelino, T., Bergenstal, R.M., Close, K.L., DeVries, J.H., et al. International consensus on use of continuous glucose monitoring. Diabetes Care 40 (2017), 1631–1640.
Phillip, M., Bergenstal, R.M., Close, K.L., Danne, T., Garg, S.K., Heinemann, L., et al. The Digital/Virtual Diabetes Clinic: the future is now-recommendations from an international panel on diabetes digital technologies introduction. Diabetes Technol Ther 23 (2021), 146–154.
Heinemann, L., Schnell, O., Gehr, B., Schloot, N.C., Gorgens, S.W., Gorgen, C, Digital diabetes management: a literature review of smart insulin pens. J Diabetes Sci Technol, 2021 Epub:1932296820983863.
Tubiana-Rufi, N., Schaepelynck, P., Franc, S., Chaillous, L., Joubert, M., Renard, E., et al. Practical implementation of automated closed-loop insulin delivery: a French position statement. Diabetes Metab, Epub, 2020, 101206.
American Diabetes Association. 1. Improving care and promoting health in populations: standards of medical care in diabetes-2021. Diabetes Care 44 (2021), S7–S14.
Grant, A.K., Golden, L, Technological advancements in the management of type 2 diabetes. Curr Diabetes Rep, 19, 2019, 163.
Scheen, A.J., Marre, M., Thivolet, C, Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and recent reports. Diabetes Metab 46 (2020), 265–271.
Caballero, A.E., Ceriello, A., Misra, A., Aschner, P., McDonnell, M.E., Hassanein, M., et al. COVID-19 in people living with diabetes: an international consensus. J Diabet Complicat, 34, 2020, 107671.